Prevalence, Incidence and Treatment Patterns of Prurigo Nodularis in England: A Retrospective Database Analysis
Prurigo nodularis (PN) is a pruritic skin disease characterised by multiple, intensely itchy skin nodules in symmetrically distributed areas of the extremities. There are very limited studies on the epidemiology and treatment pathways for PN, especially moderate-to-severe PN, from England. To assess...
Saved in:
Published in: | British journal of dermatology (1951) Vol. 191; no. 4; p. 548 |
---|---|
Main Authors: | , , , , , , , , |
Format: | Journal Article |
Language: | English |
Published: |
England
04-06-2024
|
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Abstract | Prurigo nodularis (PN) is a pruritic skin disease characterised by multiple, intensely itchy skin nodules in symmetrically distributed areas of the extremities. There are very limited studies on the epidemiology and treatment pathways for PN, especially moderate-to-severe PN, from England.
To assess the epidemiology and treatment pathways of mild and moderate-to-severe PN in England.
This retrospective cohort study used data from the Clinical Practice Research Datalink (CPRD) and Hospital Episode Statistics (HES) in England. Adult patients (≥18 years) with a PN specific diagnosis code any time between 1 April 2007 and 1 March 2019 (patient identification period) were selected. Patients were included if their first PN diagnostic code (index diagnosis date, IDD) was recorded during the identification period, with data available 6 months pre- and ≥12 months post-IDD. Patients were classified into moderate-to-severe PN (MSPN) or mild PN (MiPN) based on the presence or absence of a prescription record, post IDD, for either a systemic immunosuppressant or a gabapentinoid. Patients with MSPN and MiPN were matched 1:1 for age, gender and IDD. Prevalence and incidence were calculated for each year from 2007 to 2019. Drugs prescribed post IDD were analysed.
A total of 8,933 patients (MSPN: 2,498 patients; MiPN: 6,539 patients) were included for the study; 2,462 patients each with MiPN and MSPN were included for the comparative analysis. Atopic dermatitis, asthma and eosinophilic oesophagitis were significantly higher (all p<0.001) in patients with MSPN (vs MiPN). The prevalence of overall PN cases increased during the study period. The incidence rate also showed a similar trend. The rates of prescription of potent and super potent topical corticosteroids (TCS), topical calcineurin inhibitors, first- and second- generation antihistamines, oral and injectable systemic corticosteroid, methotrexate, antidepressants and tacrolimus were significantly higher (all p <0.001) in patients with MSPN (vs MiPN).
The epidemiology of PN was consistent with other European studies. Patients with MSPN received a significantly higher number of prescriptions for potent TCS and systemic drugs, as compared with milder patients. |
---|---|
AbstractList | Prurigo nodularis (PN) is a pruritic skin disease characterised by multiple, intensely itchy skin nodules in symmetrically distributed areas of the extremities. There are very limited studies on the epidemiology and treatment pathways for PN, especially moderate-to-severe PN, from England.
To assess the epidemiology and treatment pathways of mild and moderate-to-severe PN in England.
This retrospective cohort study used data from the Clinical Practice Research Datalink (CPRD) and Hospital Episode Statistics (HES) in England. Adult patients (≥18 years) with a PN specific diagnosis code any time between 1 April 2007 and 1 March 2019 (patient identification period) were selected. Patients were included if their first PN diagnostic code (index diagnosis date, IDD) was recorded during the identification period, with data available 6 months pre- and ≥12 months post-IDD. Patients were classified into moderate-to-severe PN (MSPN) or mild PN (MiPN) based on the presence or absence of a prescription record, post IDD, for either a systemic immunosuppressant or a gabapentinoid. Patients with MSPN and MiPN were matched 1:1 for age, gender and IDD. Prevalence and incidence were calculated for each year from 2007 to 2019. Drugs prescribed post IDD were analysed.
A total of 8,933 patients (MSPN: 2,498 patients; MiPN: 6,539 patients) were included for the study; 2,462 patients each with MiPN and MSPN were included for the comparative analysis. Atopic dermatitis, asthma and eosinophilic oesophagitis were significantly higher (all p<0.001) in patients with MSPN (vs MiPN). The prevalence of overall PN cases increased during the study period. The incidence rate also showed a similar trend. The rates of prescription of potent and super potent topical corticosteroids (TCS), topical calcineurin inhibitors, first- and second- generation antihistamines, oral and injectable systemic corticosteroid, methotrexate, antidepressants and tacrolimus were significantly higher (all p <0.001) in patients with MSPN (vs MiPN).
The epidemiology of PN was consistent with other European studies. Patients with MSPN received a significantly higher number of prescriptions for potent TCS and systemic drugs, as compared with milder patients. Prurigo nodularis (PN) is a pruritic skin disease characterized by multiple intensely itchy skin nodules in symmetrically distributed areas of the extremities. There are limited studies on the epidemiology and treatment pathways of PN, especially moderate-to-severe PN, from England.BACKGROUNDPrurigo nodularis (PN) is a pruritic skin disease characterized by multiple intensely itchy skin nodules in symmetrically distributed areas of the extremities. There are limited studies on the epidemiology and treatment pathways of PN, especially moderate-to-severe PN, from England.To assess the epidemiology and treatment pathways of mild and moderate-to-severe PN in England.OBJECTIVESTo assess the epidemiology and treatment pathways of mild and moderate-to-severe PN in England.This retrospective cohort study used data from the Clinical Practice Research Datalink and Hospital Episode Statistics in England. Adult patients (aged ≥ 18 years) with a PN-specific diagnosis code allocated any time between 1 April 2007 and 1 March 2019 (patient identification period) were selected. Patients were included if their first PN diagnostic code (index diagnosis date; IDD) was recorded during the identification period, with data available 6 months before and ≥ 12 months after the IDD. Patients were classified as having moderate-to-severe PN (MSPN) or mild PN (MiPN), based on the presence or absence of a prescription record, post-IDD, for either a systemic immunosuppressant or a gabapentinoid. Patients with MSPN and MiPN were matched 1 : 1 according to age, sex and IDD. Prevalence and incidence were calculated for each year from 2007 to 2019. Drugs prescribed post-IDD were analysed.METHODSThis retrospective cohort study used data from the Clinical Practice Research Datalink and Hospital Episode Statistics in England. Adult patients (aged ≥ 18 years) with a PN-specific diagnosis code allocated any time between 1 April 2007 and 1 March 2019 (patient identification period) were selected. Patients were included if their first PN diagnostic code (index diagnosis date; IDD) was recorded during the identification period, with data available 6 months before and ≥ 12 months after the IDD. Patients were classified as having moderate-to-severe PN (MSPN) or mild PN (MiPN), based on the presence or absence of a prescription record, post-IDD, for either a systemic immunosuppressant or a gabapentinoid. Patients with MSPN and MiPN were matched 1 : 1 according to age, sex and IDD. Prevalence and incidence were calculated for each year from 2007 to 2019. Drugs prescribed post-IDD were analysed.A total of 8933 patients (MSPN, n = 2498; MiPN, n = 6435) were included in the study; 2462 patients with MiPN and 2462 with MSPN were included for the comparative analysis. The presence of atopic dermatitis, asthma and eosinophilic oesophagitis were significantly higher (all P < 0.001) in patients with MSPN compared with those with MiPN. The overall prevalence of cases of PN increased during the study period. The incidence rate also showed a similar trend. The rates of prescription of potent and super-potent topical corticosteroids (TCS), topical calcineurin inhibitors, first- and second-generation antihistamines, oral and injectable systemic corticosteroids, methotrexate, antidepressants and tacrolimus were significantly higher (all P < 0.001) in patients with MSPN compared with those with MiPN.RESULTSA total of 8933 patients (MSPN, n = 2498; MiPN, n = 6435) were included in the study; 2462 patients with MiPN and 2462 with MSPN were included for the comparative analysis. The presence of atopic dermatitis, asthma and eosinophilic oesophagitis were significantly higher (all P < 0.001) in patients with MSPN compared with those with MiPN. The overall prevalence of cases of PN increased during the study period. The incidence rate also showed a similar trend. The rates of prescription of potent and super-potent topical corticosteroids (TCS), topical calcineurin inhibitors, first- and second-generation antihistamines, oral and injectable systemic corticosteroids, methotrexate, antidepressants and tacrolimus were significantly higher (all P < 0.001) in patients with MSPN compared with those with MiPN.The epidemiology of PN was consistent with that found in other European studies. Patients with MSPN received a significantly higher number of prescriptions for potent TCS and systemic drugs compared with patients with MiPN.CONCLUSIONSThe epidemiology of PN was consistent with that found in other European studies. Patients with MSPN received a significantly higher number of prescriptions for potent TCS and systemic drugs compared with patients with MiPN. |
Author | Bahloul, Donia Heywood, Ben Mathias, Elgan Balogh, Orsolya Hudson, Richard Hubbuck, Ellen Diribe, Onyinye Bewley, Anthony McDonald, Robert |
Author_xml | – sequence: 1 givenname: Donia orcidid: 0009-0008-9887-8159 surname: Bahloul fullname: Bahloul, Donia organization: Sanofi, Gentilly, France – sequence: 2 givenname: Richard surname: Hudson fullname: Hudson, Richard organization: Sanofi, Reading, UK – sequence: 3 givenname: Orsolya surname: Balogh fullname: Balogh, Orsolya organization: Sanofi, Reading, UK – sequence: 4 givenname: Elgan surname: Mathias fullname: Mathias, Elgan organization: Human Data Sciences, Cardiff, UK – sequence: 5 givenname: Ben surname: Heywood fullname: Heywood, Ben organization: Human Data Sciences, Cardiff, UK – sequence: 6 givenname: Ellen surname: Hubbuck fullname: Hubbuck, Ellen organization: Human Data Sciences, Cardiff, UK – sequence: 7 givenname: Onyinye surname: Diribe fullname: Diribe, Onyinye organization: Sanofi, Reading, UK – sequence: 8 givenname: Robert surname: McDonald fullname: McDonald, Robert organization: Sanofi, Reading, UK – sequence: 9 givenname: Anthony surname: Bewley fullname: Bewley, Anthony organization: Dermatology Department, Royal London Hospital, Barts Health NHS Trust, London, UK |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/38832950$$D View this record in MEDLINE/PubMed |
BookMark | eNo9kE1LAzEQhoMo2lZP3iVHQddOdvbTW6lfhaJFel-SzVS27GZrkhX6741YPc3A-8zL8IzZsekNMXYp4E5AiVO11dN2KymG_IiNBGZpFAvEYzYCgDyCMsMzNnZuCyAQUjhlZ1gUGJcpjFi_svQlWzI13fKFqRv9s3JpNF9bkr4j4_lKek_WON5v-MoOtvno-Wuvh1baxvHG8Efz0YaTez7j7-Rt73ZU--aL-IP0UklHfGZku3eNO2cnG9k6ujjMCVs_Pa7nL9Hy7Xkxny2jOhaJj5QGzFEnQmVIgAqIMlIJJUkBZaFUSMuYRJrFWVGERGmdQaJwIxRkSY4Tdv1bu7P950DOV13jamrDl9QPrsJApUWMZRnQm1-0Dn87S5tqZ5tO2n0loPoRXAXB1UFwoK8OxYPqSP-zf0bxG02HecU |
Cites_doi | 10.3414/ME11-02-0023 10.1016/j.det.2018.02.003 10.2340/00015555-3655 10.1002/ejp.767 10.3390/jcm11010095 10.1016/j.jdin.2020.10.009 10.1016/j.jaad.2020.07.025 10.2340/00015555-3518 10.1111/jdv.14570 10.1111/jdv.15107 10.1111/jdv.15040 10.1056/NEJMoa1908316 10.1016/j.jaad.2021.05.036 10.1093/ije/dyz034 10.1097/itx.0000000000000042 10.1111/bjd.21032 10.2147/CCID.S208964 10.1016/j.jaad.2018.04.047 10.3389/fmed.2022.1022889 10.1016/j.jid.2019.07.697 10.2147/CCID.S188070 10.3389/fmed.2022.1011142 10.3109/09546634.2013.814759 |
ContentType | Journal Article |
Copyright | The Author(s) 2024. Published by Oxford University Press on behalf of British Association of Dermatologists. |
Copyright_xml | – notice: The Author(s) 2024. Published by Oxford University Press on behalf of British Association of Dermatologists. |
DBID | NPM AAYXX CITATION 7X8 |
DOI | 10.1093/bjd/ljae207 |
DatabaseName | PubMed CrossRef MEDLINE - Academic |
DatabaseTitle | PubMed CrossRef MEDLINE - Academic |
DatabaseTitleList | PubMed MEDLINE - Academic |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1365-2133 |
ExternalDocumentID | 10_1093_bjd_ljae207 38832950 |
Genre | Journal Article |
GroupedDBID | --- .3N .GA 05W 0R~ 10A 1OC 23N 33P 36B 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 5GY 5HH 5LA 5RE 5VS 5WD 66C 6P2 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AABZA AACZT AAESR AAEVG AAHHS AAONW AAPXW AARHZ AAUAY AAVAP AAXRX AAZKR ABCQN ABCUV ABEJV ABNHQ ABOCM ABPTD ABPVW ABQNK ABWST ABXGK ABXVV ACAHQ ACCFJ ACCZN ACFBH ACGFS ACMXC ACPOU ACPRK ACUTJ ACXBN ADBBV ADEOM ADIPN ADIZJ ADKYN ADMGS ADOZA ADQBN ADVEK ADXAS ADZMN ADZOD AEEZP AEIMD AENEX AEQDE AEUQT AFBPY AFEBI AFGKR AFPWT AFZJQ AGQXC AGUTN AIACR AIWBW AJBDE AJEEA ALAGY ALMA_UNASSIGNED_HOLDINGS AMBMR AMYDB ATGXG ATUGU AZBYB AZVAB BAFTC BCRHZ BDRZF BHBCM BMXJE BROTX BRXPI BY8 C45 CS3 D-6 D-7 D-E D-F DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DU5 EBS ESX EX3 F00 F01 F04 F5P FUBAC G-S G.N GODZA H.X H13 HZI HZ~ IHE IX1 J0M K48 KBYEO KOP L7B LATKE LC2 LC3 LEEKS LITHE LOXES LP6 LP7 LUTES LYRES MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ NPM O66 O9- OAUYM OCZFY OIG OJZSN OPAEJ OVD OWPYF P2P P2W P2X P2Z P4B P4D Q.N Q11 QB0 R.K ROL ROX RX1 SUPJJ TEORI UB1 V9Y VVN W8V W99 WBKPD WHWMO WIH WIJ WIK WOHZO WOW WQJ WRC WUP WVDHM WXI XG1 YFH ZZTAW ~IA ~WT AAYXX CITATION 7X8 |
ID | FETCH-LOGICAL-c214t-bd0373d41b63e03b0ee6eb4e448098bb03792e15626886ebbdd604b3f1b06473 |
ISSN | 0007-0963 1365-2133 |
IngestDate | Sat Oct 26 04:05:56 EDT 2024 Fri Nov 22 03:29:48 EST 2024 Sat Nov 02 12:28:55 EDT 2024 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 4 |
Language | English |
License | The Author(s) 2024. Published by Oxford University Press on behalf of British Association of Dermatologists. |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c214t-bd0373d41b63e03b0ee6eb4e448098bb03792e15626886ebbdd604b3f1b06473 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ORCID | 0009-0008-9887-8159 |
OpenAccessLink | https://academic.oup.com/bjd/advance-article-pdf/doi/10.1093/bjd/ljae207/58084587/ljae207.pdf |
PMID | 38832950 |
PQID | 3064582399 |
PQPubID | 23479 |
ParticipantIDs | proquest_miscellaneous_3064582399 crossref_primary_10_1093_bjd_ljae207 pubmed_primary_38832950 |
PublicationCentury | 2000 |
PublicationDate | 2024-Jun-04 |
PublicationDateYYYYMMDD | 2024-06-04 |
PublicationDate_xml | – month: 06 year: 2024 text: 2024-Jun-04 day: 04 |
PublicationDecade | 2020 |
PublicationPlace | England |
PublicationPlace_xml | – name: England |
PublicationTitle | British journal of dermatology (1951) |
PublicationTitleAlternate | Br J Dermatol |
PublicationYear | 2024 |
References | Woo (2024071213254204900_ljae207-B7) 2021; 11 Bahloul (2024071213254204900_ljae207-B26) Satoh (2024071213254204900_ljae207-B12) 2020; 48 Deng (2024071213254204900_ljae207-B4) 2022; 9 Huang (2024071213254204900_ljae207-B22) 2020; 140 Kowalski (2024071213254204900_ljae207-B17) 2019; 12 Polking (2024071213254204900_ljae207-B14) 2018; 32 U.S. Food & Drug Administration (2024071213254204900_ljae207-B18) Højen (2024071213254204900_ljae207-B25) 2012; 51 Schneider (2024071213254204900_ljae207-B27) 1984; 59 Zeidler (2024071213254204900_ljae207-B11) 2018; 36 Morgan (2024071213254204900_ljae207-B20) 2022; 187 Kolli (2024071213254204900_ljae207-B29) 2019; 12 Boozalis (2024071213254204900_ljae207-B6) 2018; 79 Wolf (2024071213254204900_ljae207-B24) 2019; 48 Pereira (2024071213254204900_ljae207-B1) 2018; 32 Zeidler (2024071213254204900_ljae207-B3) 2016; 20 Stander (2024071213254204900_ljae207-B23) 2021; 2 Satoh (2024071213254204900_ljae207-B30) 2020; 48 Fostini (2024071213254204900_ljae207-B9) 2013; 24 Kwatra (2024071213254204900_ljae207-B16) Saco (2024071213254204900_ljae207-B28) 2015; 65 Stander (2024071213254204900_ljae207-B19) 2020; 100 Stander (2024071213254204900_ljae207-B15) 2020; 382 Parthasarathy (2024071213254204900_ljae207-B5) 2022; 9 Ryczek (2024071213254204900_ljae207-B21) 2020; 100 Ständer (2024071213254204900_ljae207-B13) 2020; 5 Pereira (2024071213254204900_ljae207-B10) 2018; 32 Elmariah (2024071213254204900_ljae207-B2) 2021; 84 Whang (2024071213254204900_ljae207-B8) 2022; 86 |
References_xml | – volume: 51 start-page: 529 year: 2012 ident: 2024071213254204900_ljae207-B25 article-title: Snomed CT implementation publication-title: Methods Inf Med doi: 10.3414/ME11-02-0023 contributor: fullname: Højen – volume: 36 start-page: 189 year: 2018 ident: 2024071213254204900_ljae207-B11 article-title: Prurigo nodularis and its management publication-title: Dermatol Clin doi: 10.1016/j.det.2018.02.003 contributor: fullname: Zeidler – ident: 2024071213254204900_ljae207-B16 contributor: fullname: Kwatra – volume: 100 year: 2020 ident: 2024071213254204900_ljae207-B19 article-title: Epidemiology of prurigo nodularis compared with psoriasis in Germany: a claims database analysis publication-title: Acta Derm Venereol doi: 10.2340/00015555-3655 contributor: fullname: Stander – volume: 65 start-page: 221 year: 2015 ident: 2024071213254204900_ljae207-B28 article-title: Prurigo nodularis: picking the right treatment publication-title: J Fam Pract contributor: fullname: Saco – volume: 20 start-page: 37 year: 2016 ident: 2024071213254204900_ljae207-B3 article-title: The pathogenesis of prurigo nodularis – ‘Super-Itch’ in exploration publication-title: Eur J Pain doi: 10.1002/ejp.767 contributor: fullname: Zeidler – volume: 11 start-page: 95 year: 2021 ident: 2024071213254204900_ljae207-B7 article-title: Epidemiology, comorbidities, and prescription patterns of Korean prurigo nodularis patients: a multi-institution study publication-title: J Clin Med doi: 10.3390/jcm11010095 contributor: fullname: Woo – volume: 2 start-page: 28 year: 2021 ident: 2024071213254204900_ljae207-B23 article-title: Prevalence of prurigo nodularis in the United States of America: a retrospective database analysis publication-title: JAAD Int doi: 10.1016/j.jdin.2020.10.009 contributor: fullname: Stander – volume: 84 start-page: 747 year: 2021 ident: 2024071213254204900_ljae207-B2 article-title: Practical approaches for diagnosis and management of prurigo nodularis: United States expert panel consensus publication-title: J Am Acad Dermatol doi: 10.1016/j.jaad.2020.07.025 contributor: fullname: Elmariah – volume: 48 start-page: e414-31 year: 2020 ident: 2024071213254204900_ljae207-B12 article-title: guidelines for the diagnosis and treatment of prurigo publication-title: J Dermatol contributor: fullname: Satoh – volume: 100 year: 2020 ident: 2024071213254204900_ljae207-B21 article-title: Prevalence of prurigo nodularis in Poland publication-title: Acta Derm Venereol doi: 10.2340/00015555-3518 contributor: fullname: Ryczek – volume: 32 start-page: 1059 year: 2018 ident: 2024071213254204900_ljae207-B1 article-title: European academy of dermatology and venereology European prurigo project: expert consensus on the definition, classification and terminology of chronic prurigo publication-title: J Eur Acad Dermatol Venereol doi: 10.1111/jdv.14570 contributor: fullname: Pereira – volume: 32 start-page: 2224 year: 2018 ident: 2024071213254204900_ljae207-B10 article-title: Prurigo nodularis: a physician survey to evaluate current perceptions of its classification, clinical experience and unmet need publication-title: J Eur Acad Dermatol Venereol doi: 10.1111/jdv.15107 contributor: fullname: Pereira – volume: 32 start-page: 1754 year: 2018 ident: 2024071213254204900_ljae207-B14 article-title: Prurigo Activity Score (PAS): validity and reliability of a new instrument to monitor chronic prurigo publication-title: J Eur Acad Dermatol Venereol doi: 10.1111/jdv.15040 contributor: fullname: Polking – volume: 382 start-page: 706 year: 2020 ident: 2024071213254204900_ljae207-B15 article-title: Trial of nemolizumab in moderate-to-severe prurigo nodularis publication-title: N Engl J Med doi: 10.1056/NEJMoa1908316 contributor: fullname: Stander – volume: 86 start-page: 573 year: 2022 ident: 2024071213254204900_ljae207-B8 article-title: Health-related quality of life and economic burden of prurigo nodularis publication-title: J Am Acad Dermatol doi: 10.1016/j.jaad.2021.05.036 contributor: fullname: Whang – volume: 48 year: 2019 ident: 2024071213254204900_ljae207-B24 article-title: Data resource profile: Clinical Practice Research Datalink (CPRD) Aurum publication-title: Int J Epidemiol doi: 10.1093/ije/dyz034 contributor: fullname: Wolf – volume: 5 start-page: e42 year: 2020 ident: 2024071213254204900_ljae207-B13 article-title: IFSI-guideline on chronic prurigo including prurigo nodularis publication-title: Itch doi: 10.1097/itx.0000000000000042 contributor: fullname: Ständer – ident: 2024071213254204900_ljae207-B18 contributor: fullname: U.S. Food & Drug Administration – volume: 187 start-page: 188 year: 2022 ident: 2024071213254204900_ljae207-B20 article-title: Epidemiology of prurigo nodularis in England: a retrospective database analysis publication-title: Br J Dermatol doi: 10.1111/bjd.21032 contributor: fullname: Morgan – volume: 12 start-page: 345 year: 2019 ident: 2024071213254204900_ljae207-B29 article-title: Treatment-resistant prurigo nodularis publication-title: Clin Cosmet Investig Dermatol doi: 10.2147/CCID.S208964 contributor: fullname: Kolli – volume: 79 start-page: 714 year: 2018 ident: 2024071213254204900_ljae207-B6 article-title: Ethnic differences and comorbidities of 909 prurigo nodularis patients publication-title: J Am Acad Dermatol doi: 10.1016/j.jaad.2018.04.047 contributor: fullname: Boozalis – volume: 9 start-page: 1022889 year: 2022 ident: 2024071213254204900_ljae207-B4 article-title: Extracellular matrix and dermal nerve growth factor dysregulation in prurigo nodularis compared to atopic dermatitis publication-title: Front Med (Lausanne) doi: 10.3389/fmed.2022.1022889 contributor: fullname: Deng – volume: 140 start-page: 480 year: 2020 ident: 2024071213254204900_ljae207-B22 article-title: Real-world prevalence of prurigo nodularis and burden of associated diseases publication-title: J Invest Dermatol doi: 10.1016/j.jid.2019.07.697 contributor: fullname: Huang – volume: 12 start-page: 163 year: 2019 ident: 2024071213254204900_ljae207-B17 article-title: Treatment-resistant prurigo nodularis: challenges and solutions publication-title: Clin Cosmet Investig Dermatol doi: 10.2147/CCID.S188070 contributor: fullname: Kowalski – volume: 48 start-page: e414-31 year: 2020 ident: 2024071213254204900_ljae207-B30 article-title: guidelines for the diagnosis and treatment of prurigo publication-title: J Dermatol contributor: fullname: Satoh – volume: 9 start-page: 1011142 year: 2022 ident: 2024071213254204900_ljae207-B5 article-title: Circulating plasma IL-13 and periostin are dysregulated type 2 inflammatory biomarkers in prurigo nodularis: a cluster analysis publication-title: Front Med (Lausanne) doi: 10.3389/fmed.2022.1011142 contributor: fullname: Parthasarathy – volume: 59 year: 1984 ident: 2024071213254204900_ljae207-B27 article-title: [Efficacy and safety of topical 0.05% diflorasone diacetate (florone) cream/ointment in patients with acute/chronic dermatitis] publication-title: Z Hautkr contributor: fullname: Schneider – volume: 24 start-page: 458 year: 2013 ident: 2024071213254204900_ljae207-B9 article-title: Prurigo nodularis: an update on etiopathogenesis and therapy publication-title: J Dermatolog Treat doi: 10.3109/09546634.2013.814759 contributor: fullname: Fostini – ident: 2024071213254204900_ljae207-B26 contributor: fullname: Bahloul |
SSID | ssj0013050 |
Score | 2.4922347 |
Snippet | Prurigo nodularis (PN) is a pruritic skin disease characterised by multiple, intensely itchy skin nodules in symmetrically distributed areas of the... Prurigo nodularis (PN) is a pruritic skin disease characterized by multiple intensely itchy skin nodules in symmetrically distributed areas of the extremities.... |
SourceID | proquest crossref pubmed |
SourceType | Aggregation Database Index Database |
StartPage | 548 |
Title | Prevalence, Incidence and Treatment Patterns of Prurigo Nodularis in England: A Retrospective Database Analysis |
URI | https://www.ncbi.nlm.nih.gov/pubmed/38832950 https://www.proquest.com/docview/3064582399 |
Volume | 191 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1La9wwEBabFEovpe9uX6iQnlI3kiU72t76cOghj0JdyM1IK7lNWOxlsz7033dGku1d0kJ66MUsEhqWmY-RRvpmhpA9w-e5UYYl1liBLcxMorjWidHYDEn5ElR4dfHt8PRcfS5kMZn0TcbGsf9qaRgDW2Pm7D9YexAKA_AbbA5fsDp8b2R3rMmkfSYRag9v0n3X0MCUHFjlS19WM1DglqsOQvR2v2ktclIvPEM2NvcIudArt161fU7mPpJKcfMDkaGgydbDcCyStFGRwqLzX4daT2_8ixrfuH_4qH8u2m4RDvPNhR5xZq_n_ocF2IoYJ86w1_evYcUJEilDflqx-BFRHy80UumJV3LDB3viHQ_1Md65P4z1jjv0-YoIlRtuOAvVO69tD6F0lrlE0y8utUtDx93tMtynZ9XR9-PjqizOyx1yKwUPhg5UiK_j8xTL2JDQB_8qJn6C-AMQfhBFbx91_hK_-HNMeY_cjQEI_RCQc59MXPOA3D6JFIuHpB0B9JYO8KGABTrAh_bwoW1NI3zoAB9YRSN83lNNt8BDe_DQHjyPSHlUlJ--JLErRzJPuVwnxjJxKKzkJheOCcOcy52RDuJ8NlPGwOwsdRzO1blSMGOszZk0ouYGE5vFY7LbtI17SqhM5zOZ1ZqnDgKLrDayniPXwGopZeayKdnr9VctQ-2VKnAmRAVqrqKap-R1r9sKfCM-eOnGtd1VhdF1pjB7e0qeBKUPgoSCvWyWsWc3WP2c3BmB-oLsrlede0l2rmz3yuPiNxhRj7I |
link.rule.ids | 315,782,786,27933,27934 |
linkProvider | Wiley-Blackwell |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Prevalence%2C+incidence+and+treatment+patterns+of+prurigo+nodularis+in+England%3A+a+retrospective+database+analysis&rft.jtitle=British+journal+of+dermatology+%281951%29&rft.au=Bahloul%2C+Donia&rft.au=Hudson%2C+Richard&rft.au=Balogh%2C+Orsolya&rft.au=Mathias%2C+Elgan&rft.date=2024-06-04&rft.issn=1365-2133&rft.eissn=1365-2133&rft.volume=191&rft.issue=4&rft.spage=548&rft_id=info:doi/10.1093%2Fbjd%2Fljae207&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0007-0963&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0007-0963&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0007-0963&client=summon |